Anika Therapeutics (NASDAQ:ANIK) CEO Stephen Griffin Purchases 12,200 Shares

Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Stephen Griffin acquired 12,200 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was purchased at an average price of $12.29 per share, for a total transaction of $149,938.00. Following the completion of the transaction, the chief executive officer owned 36,163 shares in the company, valued at $444,443.27. The trade was a 50.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anika Therapeutics Stock Up 0.5%

Shares of NASDAQ:ANIK opened at $12.45 on Friday. The company has a market cap of $166.84 million, a PE ratio of -15.76 and a beta of 0.28. The company’s 50-day moving average price is $14.31 and its 200 day moving average price is $11.29. Anika Therapeutics Inc. has a fifty-two week low of $7.87 and a fifty-two week high of $16.24.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.34. The firm had revenue of $29.61 million for the quarter, compared to the consensus estimate of $28.14 million. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%. As a group, equities analysts anticipate that Anika Therapeutics Inc. will post -0.61 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on ANIK. Barrington Research raised their target price on shares of Anika Therapeutics from $16.00 to $17.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Wall Street Zen raised shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $17.00.

Key Anika Therapeutics News

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: CEO insider purchase — CEO Stephen Griffin bought 12,200 shares at about $12.29, boosting his stake ~51%, a strong signal of management confidence that can support the stock. SEC Insider Filing
• Positive Sentiment: Q1 beat and operational improvement — ANIK reported Q1 EPS of $0.27 vs. a -$0.07 consensus and revenue $29.61M vs. $28.14M expected; gross margin rose to 64% and management delivered ~$4M of adjusted EBITDA, supporting a re‑rating on execution. Press Release / Slide Deck
• Positive Sentiment: Commercial momentum in core OA products — Company cites 13% total revenue growth, driven by Commercial channel strength (Monovisc, Orthovisc) and faster Integrity adoption, which investors view as recurring revenue drivers. Globe Newswire: Q1 Results
• Positive Sentiment: Analyst / bullish write‑up — A Seeking Alpha piece highlights upside as Integrity scales (510(k) cleared) and revenue momentum in 2025–2026, reinforcing the bullish narrative for investors focused on OA/regenerative growth. Bullish On Anika Therapeutics’s Pullback As Integrity Scales
• Neutral Sentiment: FY2026 revenue guidance range—Company set revenue guidance of $114.0M–$122.5M vs. consensus ~$117.2M; range overlaps consensus, leaving guidance a neutral catalyst until more detailed modeling/quarterly cadence is confirmed. FY2026 Guidance (Slide Deck)
• Neutral Sentiment: Earnings call / transcripts available — Management commentary (call transcript and summaries) provide details on OEM timing, channel mix and cost actions; useful for re‑assessing margins and cadence but no new headline items beyond results. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Regulatory and product timing risks — Growth opportunities (Hyalofast, Cingal) carry FDA timing/approval risk and the company remains broadly unprofitable on a net‑income/ROE basis historically, which could cap multiple expansion if approvals or adoption slow. Regulatory Risk Discussion

Hedge Funds Weigh In On Anika Therapeutics

Several large investors have recently bought and sold shares of ANIK. Opaleye Management Inc. increased its stake in Anika Therapeutics by 49.1% during the 2nd quarter. Opaleye Management Inc. now owns 588,797 shares of the biotechnology company’s stock valued at $6,229,000 after buying an additional 193,797 shares during the period. Capital Management Corp VA increased its stake in Anika Therapeutics by 34.8% during the 3rd quarter. Capital Management Corp VA now owns 551,248 shares of the biotechnology company’s stock valued at $5,182,000 after buying an additional 142,403 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Anika Therapeutics by 153.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 164,926 shares of the biotechnology company’s stock worth $1,585,000 after purchasing an additional 99,951 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Anika Therapeutics by 78.1% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 195,585 shares of the biotechnology company’s stock worth $1,880,000 after purchasing an additional 85,771 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Anika Therapeutics by 171.0% in the 4th quarter. Jane Street Group LLC now owns 134,768 shares of the biotechnology company’s stock worth $1,295,000 after purchasing an additional 85,029 shares during the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.